Laborie Medical Backs Venture iO Urology Investment

Based out of Portsmouth, New Hampshire, a world-leading diagnostics and therapy medical technology corporation, Laborie Medical Technologies Corporation, has acquired iO Urology. 

This venture-backed medical technology company has developed CarePath. This US FDA-approved urethral flow device is handheld at home and has been used at multiple urology clinics in the US.

CarePath's advanced protocol comes in a simple package per the manufacturer's recommendation, which allows the direct shipment of the device to the patient's home without any post office involvement and, more importantly, uses embedded cellular connectivity.

This brings in open access to accurate and reliable data, enabling the diagnosis and management of LUTS problems like BPH (benign prostatic hyperplasia). Thereby, patients find themselves conversing about voids, functions, and BPH with their clinicians and even checking out treatment options that can mitigate their lives.

It is reported as a clinical entity with up to 14 million American men displaying symptoms of BPH; without treatment, BPH can evolve into more advanced diseases such as bladder and kidney diseases. 

The prevalent attitude among the sufferers about BPH, which is low awareness and education, is blamed for poor compliance and patient involvement problems over the years. Most patients usually seek this type of specialist care from a urologist. After being assessed by the urologist, many of them end up with a prescription for oral therapy; nevertheless, a small number of ones did choose to come back for a follow-up appointment.